Roger Perlmutter, Eikon CEO
January 6, 2022 07:00 AM ESTUpdated 12:45 PM
R&D

In new post-Mer­ck role, Roger Perl­mut­ter rakes in half a bil­lion dol­lars to change the way sci­en­tists look at pro­teins

Nicole DeFeudis

Editor

Roger Perl­mut­ter hasn’t wast­ed any time since an­nounc­ing his sup­posed re­tire­ment from Mer­ck in Oc­to­ber 2020. Af­ter leav­ing his perch as one of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times